← Back to Search

Cholinergic Agonist

Aceclidine ophthalmic solution for Presbyopia

Phase 2
Waitlist Available
Research Sponsored by Alisyn Facemire
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour post treatment
Awards & highlights

Study Summary

This trial is testing a new eye drop medication for people with presbyopia (age-related vision loss). The drop contains two drugs, and the trial will compare it to a drop with just one of those drugs, and to a fake (vehicle) drop.

Eligible Conditions
  • Presbyopia
  • Refractive Errors
  • Eye Diseases
  • Near Vision
  • Constricted Pupil

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Efficacy Variable

Trial Design

3Treatment groups
Experimental Treatment
Group I: Vehicle Ophthalmic Solution dosed bilaterallyExperimental Treatment1 Intervention
Proprietary vehicle ophthalmic solution
Group II: Combination ophthalmic solution (LNZ101) dosed bilaterallyExperimental Treatment2 Interventions
LENZ 101: Aceclidine/Brimonidine combination ophthalmic solution
Group III: Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterallyExperimental Treatment2 Interventions
LENZ 100: Aceclidine ophthalmic solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aceclidine
FDA approved
Aceclidine
FDA approved
Vehicle proprietary ophthalmic solution
2022
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Alisyn FacemireLead Sponsor
ORA, Inc.Industry Sponsor
69 Previous Clinical Trials
8,978 Total Patients Enrolled
5 Trials studying Presbyopia
1,151 Patients Enrolled for Presbyopia
Alisyn Facemire, BAStudy DirectorLENZ Therapeutics
3 Previous Clinical Trials
1,059 Total Patients Enrolled
3 Trials studying Presbyopia
1,059 Patients Enrolled for Presbyopia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What site did they apply to?
INSIGHT Study Site #5
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Alisyn Facemire 2022. "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05431543.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top